Image Credit: Shutterstock
New Delhi-based Mankind Pharma has entered into an agreement with Dr Reddy’s Laboratories in Hyderabad to acquire two of its brands Combihale and Daffy.
Combihale is used for the treatment of asthma and chronic obstructive pulmonary disease. The market for this category is valued at ~ Rs 900 crores growing at 14 per cent (IQVIA). The acquisition of Combihale is expected to strengthen Mankind’s presence in the inhalation respiratory market segment.
Daffy is a soap-free moisturising bar for infant babies. The total market for this category is valued at ~ Rs 1000 crores growing at 18 per cent (IQVIA).
As per the terms of the definitive agreement executed between the companies, Mankind Pharma will take over the manufacturing, marketing and distribution of both products in India. The entire integration and transition of the brands are expected to be completed by March 2022.
